TMCnet News
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
[December 11, 2020]
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
â Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment â â Statistically Significant Difference of Duration of Immune Response of NPS vs. Control: p=0.000094 - Â Â
â Data to be Presented Today at the San Antonio Breast Cancer Symposium -
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (âSELLASâ or the âCompanyâ), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, announced today final data with up to 6 months follow-up from a Phase 2 randomiz
Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in
E-Mail
BOSTON - Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women s Cancer Center investigators shows.
The report, coupled with earlier findings that combining checkpoint inhibitors with chemotherapy can increase response rates in patients with early-stage triple-negative breast cancer, offer assurance that the benefits of the combination can be achieved without diminishing patients quality of life, the study authors say. The study, to be presented at today s virtual session of the San Antonio Breast Cancer Symposium, by Elizabeth Mittendorf, MD, PhD Director of the Breast Immuno-Oncology program at the Dana-Farber/Brigham and Women s Cancer Center, is the first to use patients own feedback to gauge the impact of the combination therapy on daily functioning for p
GLSI Stock: Why Greenwich LifeSciences Is Up 2,000% Today Greenwich LifeSciences says its GP2 treatment reduced breast cancer recurrences to 0% By Sarah Smith, InvestorPlace Web Content Producer Dec 9, 2020, 2:33 pm EDT December 18, 2020
Greenwich LifeSciences (NASDAQ:
GLSI) before today, but that is not stopping GLSI stock from soaring more than 2,000% on Wednesday. This comes as the biopharmaceutical company shared promising results on its breast cancer treatment. Additionally, it is making plans to advance its clinical trials. So, what do you need to know today?
Source: Photographee.eu / Shutterstock.com
To start, what exactly is Greenwich LifeSciences? Well, Greenwich is a clinical-stage biopharmaceutical company that calls Texas its home. And importantly, Greenwich is behind a new treatment to prevent recurrences of breast cancer.
Immunotherapy improves responses without reducing quality of life in early breast cancer medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.